PDF(Pubmed)
Abstract：
UNASSIGNED: Evaluate available evidence of physical and/or chemical compatibility of commonly used medications in critically ill patients with balanced crystalloids.
UNASSIGNED: Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews were queried from inception to September 2022.
UNASSIGNED: This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. English-language studies reporting physical and/or chemical compatibility data between 50 selected medications and balanced crystalloids were included. A previously designed tool to assess risk of bias was adapted for use.
UNASSIGNED: Twenty-nine studies encompassing 39 (78%) medications and 188 unique combinations with balanced crystalloids were included. Combinations included 35 (70%) medications with lactated Ringer\'s, 26 (52%) medications with Plasma-Lyte, 10 (20%) medications with Normosol, and one (2%) medication with Isolyte. Studies commonly evaluated physical and chemical compatibility (55.2%). More medications were evaluated via Y-site than admixture. Incompatibilities were identified in 18% of combinations comprising 13 individual drugs.
UNASSIGNED: This systematic review evaluates the compatibility of select critical care medications with balanced crystalloid solutions. Results may be used as a tool to guide clinicians on balanced crystalloid compatibility, potentially increasing ubiquitous use and reducing patient exposure to normal saline.
UNASSIGNED: Data are limited regarding chemical/physical compatibility of commonly used medications in critically ill patients with balanced crystalloids. Additional compatibility studies are warranted, particularly methodologically rigorous studies assessing Plasma-Lyte, Normosol, and Isolyte. Of the evaluated medications, there was a low frequency of incompatibilities with balanced crystalloids.
UNASSIGNED: Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews were queried from inception to September 2022.
UNASSIGNED: This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. English-language studies reporting physical and/or chemical compatibility data between 50 selected medications and balanced crystalloids were included. A previously designed tool to assess risk of bias was adapted for use.
UNASSIGNED: Twenty-nine studies encompassing 39 (78%) medications and 188 unique combinations with balanced crystalloids were included. Combinations included 35 (70%) medications with lactated Ringer\'s, 26 (52%) medications with Plasma-Lyte, 10 (20%) medications with Normosol, and one (2%) medication with Isolyte. Studies commonly evaluated physical and chemical compatibility (55.2%). More medications were evaluated via Y-site than admixture. Incompatibilities were identified in 18% of combinations comprising 13 individual drugs.
UNASSIGNED: This systematic review evaluates the compatibility of select critical care medications with balanced crystalloid solutions. Results may be used as a tool to guide clinicians on balanced crystalloid compatibility, potentially increasing ubiquitous use and reducing patient exposure to normal saline.
UNASSIGNED: Data are limited regarding chemical/physical compatibility of commonly used medications in critically ill patients with balanced crystalloids. Additional compatibility studies are warranted, particularly methodologically rigorous studies assessing Plasma-Lyte, Normosol, and Isolyte. Of the evaluated medications, there was a low frequency of incompatibilities with balanced crystalloids.
摘要：
■评估晶体平衡的危重患者常用药物的物理和/或化学相容性的现有证据。
■OvidMEDLINE,Embase,Cochrane中央控制试验登记册,和Cochrane系统审查数据库从成立到2022年9月进行了查询。
■本综述按照系统综述和荟萃分析指南的首选报告项目进行。包括报告50种选定药物和平衡晶体之间的物理和/或化学相容性数据的英语研究。以前设计的评估偏倚风险的工具被调整使用。
■包括29项研究，包括39项（78％）药物和188种具有平衡晶体的独特组合。组合包括35种（70％）药物与乳酸林格，26（52％）使用血浆-Lyte的药物，10（20％）药物与Normosol，和一种（2％）使用Isolyte的药物。研究通常评估物理和化学相容性（55.2％）。通过Y位点评估的药物多于混合物。在包含13种单独药物的18％的组合中发现了不相容性。
■本系统评价评价了部分重症监护药物与平衡晶体溶液的相容性。结果可用作指导临床医生平衡晶体相容性的工具，潜在的增加无处不在的使用和减少患者暴露于生理盐水。
■关于晶体平衡的危重患者常用药物的化学/物理相容性的数据有限。额外的兼容性研究是必要的，特别是在方法上严格的研究评估血浆-Lyte，Normosol,和Isolyte.在评估的药物中，与平衡晶体不相容的频率很低。
■OvidMEDLINE,Embase,Cochrane中央控制试验登记册,和Cochrane系统审查数据库从成立到2022年9月进行了查询。
■本综述按照系统综述和荟萃分析指南的首选报告项目进行。包括报告50种选定药物和平衡晶体之间的物理和/或化学相容性数据的英语研究。以前设计的评估偏倚风险的工具被调整使用。
■包括29项研究，包括39项（78％）药物和188种具有平衡晶体的独特组合。组合包括35种（70％）药物与乳酸林格，26（52％）使用血浆-Lyte的药物，10（20％）药物与Normosol，和一种（2％）使用Isolyte的药物。研究通常评估物理和化学相容性（55.2％）。通过Y位点评估的药物多于混合物。在包含13种单独药物的18％的组合中发现了不相容性。
■本系统评价评价了部分重症监护药物与平衡晶体溶液的相容性。结果可用作指导临床医生平衡晶体相容性的工具，潜在的增加无处不在的使用和减少患者暴露于生理盐水。
■关于晶体平衡的危重患者常用药物的化学/物理相容性的数据有限。额外的兼容性研究是必要的，特别是在方法上严格的研究评估血浆-Lyte，Normosol,和Isolyte.在评估的药物中，与平衡晶体不相容的频率很低。
